PORTLAND, Ore., Nov. 21, 2016 /PRNewswire/ -- Paragon BioTeck, Inc. (Paragon), announces a monumental ruling handed down by the United States Patent and Trademark Office affirming claims made by Paragon in the patent for its R-phenylephrine hydrochloride formulation. Paragon is a privately held pharmaceutical and medical device company specializing in the development and commercialization of ophthalmic pharmaceuticals, devices and therapies. In late 2015, Altaire Pharmaceuticals, Inc., sought to invalidate Paragon's patent that claims a method of maintaining purity of the formulation. In only the fourth written decision by the Patent Trial and Appeals Board, the ruling affirms that the petition by Altaire Pharmaceuticals was without merit. "While our belief in the strength of our patent was never in doubt, this is a tremendous win for Paragon BioTeck. This continues to reaffirm our belief and company mission behind the science and products we develop," said Patrick Witham, President & CEO. Paragon is strongly dedicated to addressing unmet and underserved medical needs through product development that is based on cutting-edge science. Since its inception, Paragon has sought to partner with leading scientists and thinkers to drive innovations that advance patient care and improve the quality of lives around the world. The patent ruling both reinforces the strong science underlying the formulation of Paragon's Phenylephrine Hydrochloride Ophthalmic Solution and substantiates the operational philosophy of the company. Phenylephrine hydrochloride is widely used by eye care professionals to attain mydriasis (dilation of the pupil) for conducting an ocular examination. It is an indispensable tool for the early detection, diagnosis and treatment of serious eye diseases and is vital in managing ocular health. About Phenylephrine Hydrochloride Ophthalmic SolutionPhenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10%, is an alpha-1 adrenergic receptor agonist used for dilation of the pupil due to its vasoconstrictor and mydriatic action. Phenylephrine possesses predominantly adrenergic effects. In the eye, phenylephrine acts locally as a potent vasoconstrictor and mydriatic by constricting ophthalmic blood vessels and the radial muscle of the iris.